Biotech Verona Pharma: A 363% Return Thanks To Big Pharma's Myopia Merck plans to acquire Verona Pharma for $10 billion, or $107 per share — a 363% gain for the Innovation & Freedom Portfolio.
Biotech Journey Medical Corporation: Why It Might Be Worth Having A Skin In This Game Journey Medical's newly approved Emrosi™ outperformed Oracea® in two Phase III trials. If it captures a significant share of Oracea's $300m market, Journey could be significantly undervalued.
